Last updated on May 2017

S1216 Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Brief description of study

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Clinical Study Identifier: NCT01809691

Contact Investigators or Research Sites near you

Start Over

Asit K. Paul

Lynchburg Hematology-Oncology Clinic
Lynchburg, VA United States
  Connect »